December 8, 2021: Today, the Centers for Disease Control and Prevention (CDC) published its updated Clinical Practice Guideline for Preexposure Prophylaxis for HIV Prevention and Clinical Providers Supplement. The updated guideline and supplement reflect the latest science and are intended to help physicians effectively prescribe all FDA-approved pre-exposure prophylaxis (PrEP) medications to patients and increase PrEP use among all people who could benefit.

Click here to view key revisions to the guidelines and the full announcement.

Preexposure Prophylaxis for the Prevention of HIV Infection in the United States (2021 Update) – Clinical Providers Supplement pdf icon [PDF – 764 KB]

Preexposure Prophylaxis for the Prevention of HIV Infection in the United States (2021 Update) – Clinical Practice Guideline pdf icon [PDF – 2 MB]

Specific pages with updates useful in clinic:

• Page 15 – Table 1a: Summary of Clinician Guidance for Daily Oral PrEP Use
• Page 16 -17 – Table 1b: Summary of Clinician Guidance for Cabotegravir Injection PrEP Use
• Page 23 – Figure 2 Assessing Indications for PrEP in Sexually Active Persons
• Page 27 – Figure 3 Assessing Indications for PrEP in Persons Who Inject Drugs
• Page 30 – Figure 4a Clinician Determination of HIV Status for PrEP Provision to Persons without Recent Antiretroviral Prophylaxis Use [Sara: (If lab says “x” then “y”)]
• Page 31 – Figure 4b Clinician Determination of HIV Status for PrEP Provision to Persons with Recent or Ongoing Antiretroviral Prophylaxis Use
• Page 35 – Same Day PrEP Guidance
• Page 40 – PrEP Telehealth Guidance & Medication Adherence Counseling
• Page 43 – Follow up Care & Monitoring Guidance
• Page 47 – Prescribing Cabotegravir Injection Guidance
• Page 55 – Event Driven PrEP
• Page 64 – Primary Care Considerations around PrEP
• Page 65 – Financial / Billing Issues